Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ANI PharmaceuticalsANIP -5.35%80 EV-to-OCF is 9.67 as of Aug. 08, 2026, which is 43% below its 10-year median of 16.82. GuruFocus rates ANIP with a GF Score™ of 80/100 and a GF Value™ of $101.57 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 1,007 Drug Manufacturers companies, ANI Pharmaceuticals ranks better than 51.04% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, ANI Pharmaceuticals's Enterprise Value is $2,018.2 Mil.
ANI Pharmaceuticals's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 was $208.6 Mil. Therefore, ANI Pharmaceuticals's EV-to-OCF for today is 9.67.
The historical rank and industry rank for ANI Pharmaceuticals's EV-to-OCF or its related term are showing as below:
ANIP'
s EV-to-OCF Range Over the Past 10 Years
Min: -32.22 Med: 16.82 Max: 260.57
Current: 9.67
During the past 13 years, the highest EV-to-OCF of ANI Pharmaceuticals was 260.57. The lowest was -32.22. And the median was 16.82.
ANIP's EV-to-OCF is ranked better than 51.04% of 1007
companies
in the Drug Manufacturers industry
Industry Median: 10.87
vs ANIP: 9.67
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
ANI Pharmaceuticals (NAS:ANIP) EV-to-OCF Explanation
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
ANI Pharmaceuticals's PE Ratio (TTM) for today is calculated as:
ANI Pharmaceuticals's share price for today is $78.45.
ANI Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $3.950.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
ANI Pharmaceuticals EV-to-OCF Related Terms
ANI Pharmaceuticals EV-to-OCF Historical Data
* Premium members only.
The historical data trend for ANI Pharmaceuticals's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, ANI Pharmaceuticals's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ANI Pharmaceuticals EV-to-OCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, ANI Pharmaceuticals's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where ANI Pharmaceuticals's EV-to-OCF falls into.
ANI Pharmaceuticals's current Enterprise Value is $2,018.2 Mil.
ANI Pharmaceuticals's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $208.6 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ANI Pharmaceuticals (ANIP) has a EV-to-OCF of 9.67 as of Aug. 08, 2026. This is 43% below median its historical median of 16.82. According to the industry distribution chart, ANI Pharmaceuticals ranks #493 out of 1007 companies in the Drug Manufacturers industry, placing it in the top 49%.
Is ANI Pharmaceuticals' EV-to-OCF too high?
ANI Pharmaceuticals' current EV-to-OCF of 9.67 is 43% below median its 10-year median of 16.82. The Drug Manufacturers industry median EV-to-OCF is 10.87. ANI Pharmaceuticals' value of 9.67 is 11% below this industry median. Based on the distribution chart, ANI Pharmaceuticals ranks #493 out of 1007 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, ANI Pharmaceuticals has a GF Score™ of 80/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does ANI Pharmaceuticals' EV-to-OCF compare to TRLV and AMLX?
According to the Drug Manufacturers industry distribution chart, ANI Pharmaceuticals ranks #493 out of 1007 companies for EV-to-OCF. This puts ANI Pharmaceuticals in the upper half of its industry. The industry median EV-to-OCF is 10.87. ANI Pharmaceuticals' value of 9.67 is 11% below this benchmark. While the company's 10-year median is 16.82 vs. the industry median of 10.87, ANI Pharmaceuticals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Drug Manufacturers company?
The median EV-to-OCF among Drug Manufacturers companies is 10.87, based on 1,007 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-OCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ANI Pharmaceuticals's current EV-to-OCF of 9.67 is 11% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median EV-to-OCF is 10.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ANI Pharmaceuticals's current EV-to-OCF is 9.67, which is 43% below median its own 10-year median of 16.82. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ANI Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, ANI Pharmaceuticals (ANIP) is currently considered Modestly Undervalued. The stock's GF Value™ is $101.57, compared to a current price of $78.45 — trading 22.8% below its estimated fair value. The current EV-to-OCF is 9.67, which is 43% below median its 10-year median of 16.82 and 11% below the Drug Manufacturers industry median of 10.87. ANI Pharmaceuticals' overall GF Score™ is 80/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For ANI Pharmaceuticals (ANIP), the current EV-to-OCF is 9.67 as of Aug. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ANI Pharmaceuticals (ANIP) Overvalued in 2026?
Based on GuruFocus' analysis, ANI Pharmaceuticals stock appears to be undervalued.
The current stock price of $78.45 is trading 22.8% below its estimated GF Value™ of $101.57.
GuruFocus considers ANI Pharmaceuticals to be Modestly Undervalued.
Key valuation signals for ANIP:
EV-to-OCF: 9.67 (43% below median its 10-year median of 16.82)
GF Value™: $101.57 vs. price of $78.45 (22.8% below fair value)
Industry Position: 11% below the Drug Manufacturers median (#493 of 1007)
No single metric tells the full story. See the ANIP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ANI Pharmaceuticals Inc is a diversified biopharmaceutical company. It is focused on developing, manufacturing, and commercializing therapeutics through its Rare Disease business, which markets novel products in the areas of ophthalmology, rheumatology, nephrology, neurology, and pulmonology; and through its Generics and Brands businesses. The firm's product portfolio comprises Purified Cortrophin Gel, ILUVIEN, and YUTIQ (fluocinolone acetonide intravitreal implant), among others. Additionally, its Generics portfolio includes several products with a wide variety of indications. The company has two operating segments: Rare Disease and Brands, which derive maximum revenue, and Generics and Other. Geographically, it generates maximum revenue from the United States, followed by other markets.
80GF Score
Get the complete analysis for ANIP
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ANIP has been successfully added to your 
